Therapeutic potential of pancreatic PAX4-regulated pathways in treating diabetes mellitus. 2018

Petra I Lorenzo, and Nadia Cobo-Vuilleumier, and Benoit R Gauthier
Andalusian Center for Molecular Biology and Regenerative Medicine - CABIMER, Junta de Andalucia - University of Pablo de Olavide - University of Seville - CSIC, Seville 41092, Spain.

The high prevalence of diabetes mellitus (DM) in our society, together with the fact that current treatments are only palliative and do not prevent the development of life threatening side effects, highlights the urgent need for novel therapies targeting the root cause of the disease. Independent of the etiology of DM, the definitive therapeutic approach will imply the restitution of an adequate functional β-cell mass capable of compensating for the insulin demand of the organism. The recent demonstration of heterogeneity within the islets as well as their innate plasticity has encouraged the development of studies aiming at potentiation of the regenerative capacity of islets. In this regard, factors implicated in pancreas ontogeny as well as in the adaptation processes that take place in the islets under situations of increased insulin demand have gained much interest. One of these factors is the transcription factor PAX4, required for β-cell formation during embryonic development and implicated in adult β-cell adaptation under stress situations. Here we review the therapeutic potential of PAX4 as well as its downstream targets for the development of novel treatments for DM.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004059 Diffusion of Innovation The broad dissemination of new ideas, procedures, techniques, materials, and devices and the degree to which these are accepted and used. Innovation Diffusion,Diffusion, Innovation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000066670 Cell Plasticity The ability of a cell to change its PHENOTYPE in response to changes in the environment. Cellular Plasticity,Cell Plasticities,Cellular Plasticities,Plasticities, Cell,Plasticities, Cellular,Plasticity, Cell,Plasticity, Cellular
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal

Related Publications

Petra I Lorenzo, and Nadia Cobo-Vuilleumier, and Benoit R Gauthier
January 2005, Clinical calcium,
Petra I Lorenzo, and Nadia Cobo-Vuilleumier, and Benoit R Gauthier
January 2009, Eksperimental'naia i klinicheskaia farmakologiia,
Petra I Lorenzo, and Nadia Cobo-Vuilleumier, and Benoit R Gauthier
May 2015, Expert review of endocrinology & metabolism,
Petra I Lorenzo, and Nadia Cobo-Vuilleumier, and Benoit R Gauthier
October 1981, The Medical journal of Australia,
Petra I Lorenzo, and Nadia Cobo-Vuilleumier, and Benoit R Gauthier
December 2008, Deutsche medizinische Wochenschrift (1946),
Petra I Lorenzo, and Nadia Cobo-Vuilleumier, and Benoit R Gauthier
December 2020, Journal of diabetes and metabolic disorders,
Petra I Lorenzo, and Nadia Cobo-Vuilleumier, and Benoit R Gauthier
January 2014, Vitamins and hormones,
Petra I Lorenzo, and Nadia Cobo-Vuilleumier, and Benoit R Gauthier
July 1998, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Petra I Lorenzo, and Nadia Cobo-Vuilleumier, and Benoit R Gauthier
January 2022, Frontiers in pharmacology,
Petra I Lorenzo, and Nadia Cobo-Vuilleumier, and Benoit R Gauthier
February 2023, Diabetology & metabolic syndrome,
Copied contents to your clipboard!